1. Home
  2. REPL vs GLOB Comparison

REPL vs GLOB Comparison

Compare REPL & GLOB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

N/A

Current Price

$12.88

Market Cap

1.4B

Sector

Health Care

ML Signal

N/A

Logo Globant S.A.

GLOB

Globant S.A.

N/A

Current Price

$37.86

Market Cap

1.3B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
REPL
GLOB
Founded
2015
2003
Country
United States
Luxembourg
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
2018
2015

Fundamental Metrics

Financial Performance
Metric
REPL
GLOB
Price
$12.88
$37.86
Analyst Decision
Hold
Buy
Analyst Count
9
15
Target Price
$5.67
$71.60
AVG Volume (30 Days)
2.2M
995.2K
Earning Date
05-21-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$2.98
Revenue Next Year
N/A
$5.18
P/E Ratio
N/A
$22.55
Revenue Growth
N/A
N/A
52 Week Low
$1.50
$27.56
52 Week High
$16.33
$72.10

Technical Indicators

Market Signals
Indicator
REPL
GLOB
Relative Strength Index (RSI) 42.98 51.27
Support Level $6.81 $35.68
Resistance Level $16.02 $38.97
Average True Range (ATR) 0.71 1.56
MACD -0.45 -0.16
Stochastic Oscillator 14.89 51.33

Price Performance

Historical Comparison
REPL
GLOB

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

About GLOB Globant S.A.

Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.

Share on Social Networks: